Magnesium ( DrugBank: Magnesium )

19 diseases

ID	Disease name (Link within this page)	Number of trials
3	Spinal muscular atrophy	1
6	Parkinson disease	2
11	Myasthenia gravis	1
13	Multiple sclerosis/Neuromyelitis optica	1
15	Inclusion body myositis	1
46	Malignant rheumatoid arthritis	1
64	Thrombotic thrombocytopenic purpura	1
70	Spinal stenosis	1
93	Primary biliary cholangitis	2
97	Ulcerative colitis	1
166	Pseudoxanthoma elasticum	1
225	Congenital nephrogenic diabetes insipidus	1
235	Hypoparathyroidism	1
256	Muscle glycogenosis	1
284	Diamond-Blackfan anemia	2
291	Hirschsprung disease, entire colon type	1
296	Biliary atresia	1
297	Alagille syndrome	1
298	Hereditary pancreatitis	3

3. Spinal muscular atrophy

Clinical trials : 217 / Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05272969 (ClinicalTrials.gov)	March 31, 2022	28/1/2022	Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD)	Pompe Disease (Late-onset);Inclusion Body Myositis;Spinal Muscular Atrophy Type 3;FSHD	Diagnostic Test: Beck depression inventory fast screen (Questionnaire);Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire);Diagnostic Test: German Pain Inventory (Questionnaire);Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire);Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire);Diagnostic Test: R-PAct (Questionnaire);Diagnostic Test: Quick Motor Function Test;Diagnostic Test: Handheld Dynamometry (HHD);Diagnostic Test: Six-minute walk test (6MWT);Diagnostic Test: Pressure pain threshold;Diagnostic Test: Muscle ultrasound;Diagnostic Test: Vital signs;Diagnostic Test: Borg Scale;Diagnostic Test: Laboratory assessment: Creatine kinase;Diagnostic Test: Laboratory assessment: Vitamin D Level;Diagnostic Test: Laboratory assessment: calcium;Diagnostic Test: Laboratory assessment: magnesium;Diagnostic Test: Laboratory assessment: phosphate;Genetic: Genetic test: ACE polymorphism;Genetic: Genetic test: ACTN3 polymorphism;Genetic: Blood draw for optional genetic exome sequencing	LMU Klinikum	NULL	Not yet recruiting	18 Years	N/A	All	95		Germany

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000022022	2016/05/10	10/05/2016	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease	Parkinson diseaseChronic constipation	Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment	Dokkyo Medical University	NULL	Complete: follow-up complete	20years-old	90years-old	Male and Female	64	Not selected	Japan
2	JPRN-UMIN000022023	2016/05/10	10/05/2016	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-		Parkinson diseaseChronic constipation	Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen	Dokkyo Medical University	NULL	Complete: follow-up complete	20years-old	90years-old	Male and Female	64	Not selected	Japan

11. Myasthenia gravis

Clinical trials : 315 / Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800017696	2016-07-01	2018-08-10	Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis	Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis	Myasthenia Gravis	Group A:Magnesium Sulfate;Group B:Normal saline;	The University of Hong Kong-Shenzhen Hospital	NULL	Recruiting	18	60	Both	Group A:30;Group B:30;		China

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01381354 (ClinicalTrials.gov)	October 2010	26/5/2011	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis	Other: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oil	University of Iowa	Direct MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLC	Completed	18 Years	65 Years	All	38	Phase 1	United States

15. Inclusion body myositis

Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05272969 (ClinicalTrials.gov)	March 31, 2022	28/1/2022	Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD)	Pompe Disease (Late-onset);Inclusion Body Myositis;Spinal Muscular Atrophy Type 3;FSHD	Diagnostic Test: Beck depression inventory fast screen (Questionnaire);Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire);Diagnostic Test: German Pain Inventory (Questionnaire);Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire);Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire);Diagnostic Test: R-PAct (Questionnaire);Diagnostic Test: Quick Motor Function Test;Diagnostic Test: Handheld Dynamometry (HHD);Diagnostic Test: Six-minute walk test (6MWT);Diagnostic Test: Pressure pain threshold;Diagnostic Test: Muscle ultrasound;Diagnostic Test: Vital signs;Diagnostic Test: Borg Scale;Diagnostic Test: Laboratory assessment: Creatine kinase;Diagnostic Test: Laboratory assessment: Vitamin D Level;Diagnostic Test: Laboratory assessment: calcium;Diagnostic Test: Laboratory assessment: magnesium;Diagnostic Test: Laboratory assessment: phosphate;Genetic: Genetic test: ACE polymorphism;Genetic: Genetic test: ACTN3 polymorphism;Genetic: Blood draw for optional genetic exome sequencing	LMU Klinikum	NULL	Not yet recruiting	18 Years	N/A	All	95		Germany

46. Malignant rheumatoid arthritis

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TCC-12002824	2008-07-10	2012-12-08	Traditional Chinese and anti-rheumatic drugs for the treatment of rheumatoid arthritis	Integration of Traditional Chinese and Western Medicine treat rheumatoid witharthritis: A prospective, randomized, controlled trial	rheumatoid arthritis with peptic ulcer	Acupuncture treatment:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint. ;ARD treatment:esomeprazole magnesium enteric-coated tablets ,celecoxib capsules and methotrexate tablets ;Combined therapy:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint + oral Shanhuang Wuji decoction ;	Hospital of Chengdu Military Area Command PLA	NULL	Completed	45	65	Both	Acupuncture treatment:20;ARD treatment:20;Combined therapy:20;		China

64. Thrombotic thrombocytopenic purpura

Clinical trials : 86 / Drugs : 81 - (DrugBank : 20) / Drug target genes : 16 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03237819 (ClinicalTrials.gov)	May 27, 2018	13/6/2017	Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care	Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial	Thrombotic Thrombocytopenic Purpura	Drug: Sulfate, Magnesium;Drug: Placebo - Concentrate	Assistance Publique - Hôpitaux de Paris	NULL	Active, not recruiting	18 Years	N/A	All	74	Phase 3	France

70. Spinal stenosis

Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04391855 (ClinicalTrials.gov)	May 10, 2020	13/5/2020	Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery	Effect of Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Sulfate as Adjuncts to the Local Anesthetic on Pain Relief After Spine Surgery	Analgesia;Pain, Postoperative;Spinal Stenosis;Spinal Disease	Drug: Tramadol with ropivacaine;Drug: Dexmedetomidine with ropivacaine;Drug: Magnesium with ropivacaine;Drug: Ropivacaine plus normal saline	Aristotle University Of Thessaloniki	NULL	Recruiting	18 Years	80 Years	All	78	Phase 4	Greece

93. Primary biliary cholangitis

Clinical trials : 282 / Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05133336 (ClinicalTrials.gov)	March 15, 2022	1/11/2021	Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis	Primary Biliary Cholangitis	Drug: Saroglitazar Magnesium 1 mg;Drug: Saroglitazar Magnesium 2 mg;Drug: Placebo	Zydus Therapeutics Inc.	NULL	Not yet recruiting	18 Years	75 Years	All	192	Phase 2/Phase 3	NULL
2	NCT03112681 (ClinicalTrials.gov)	August 18, 2017	10/4/2017	Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis	A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )	Primary Biliary Cirrhosis	Drug: Saroglitazar magnesium 2 mg;Drug: Saroglitazar magnesium 4 mg;Drug: Placebo Oral Tablet	Zydus Discovery DMCC	NULL	Active, not recruiting	18 Years	75 Years	All	37	Phase 2	United States

97. Ulcerative colitis

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03581149 (ClinicalTrials.gov)	March 26, 2018	27/3/2018	Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients	Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial	Ulcerative Colitis	Drug: Sodium Picosulfate/Magnesium Citrate Laxative;Drug: 2L polyethylene glycol/ascorbic acid	American University of Beirut Medical Center	NULL	Recruiting	18 Years	65 Years	All	68	Phase 4	Lebanon

166. Pseudoxanthoma elasticum

Clinical trials : 15 / Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01525875 (ClinicalTrials.gov)	August 2012	1/2/2012	Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Magnesium Oxide;Drug: Placebo	Mark Lebwohl	NULL	Completed	18 Years	N/A	All	44	Phase 2	United States

225. Congenital nephrogenic diabetes insipidus

Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-003360-56-DK (EUCTR)	28/08/2009	07/07/2009	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Kongenit nefrogen diabetes insipidus MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Confortid INN or Proposed INN: INDOMETACIN Trade Name: Losec INN or Proposed INN: OMEPRAZOLE MAGNESIUM Trade Name: Viagra Other descriptive name: SILDENAFIL CITRATE Trade Name: Miacalcic Other descriptive name: CALCITONIN (SALMON) Trade Name: Spirix Other descriptive name: SPIRONOLACTONE Trade Name: Esidrix Product Name: Esidrix INN or Proposed INN: HYDROCHLOROTHIAZIDE	Dept. of Pediatrics, The Childrens Hospital, Denver	NULL	Not Recruiting			Female: no Male: yes	40		Denmark

235. Hypoparathyroidism

Clinical trials : 88 / Drugs : 128 - (DrugBank : 25) / Drug target genes : 5 - Drug target pathways : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00824226 (ClinicalTrials.gov)	January 2009	15/1/2009	Magnesium Treatment in Hypoparathyroidism	Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients	Hypoparathyroidism	Dietary Supplement: magnesium	University of Tartu	NULL	Completed	18 Years	N/A	Both	10	N/A	Estonia

256. Muscle glycogenosis

Clinical trials : 180 / Drugs : 153 - (DrugBank : 30) / Drug target genes : 31 - Drug target pathways : 134

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05272969 (ClinicalTrials.gov)	March 31, 2022	28/1/2022	Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD)	Pompe Disease (Late-onset);Inclusion Body Myositis;Spinal Muscular Atrophy Type 3;FSHD	Diagnostic Test: Beck depression inventory fast screen (Questionnaire);Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire);Diagnostic Test: German Pain Inventory (Questionnaire);Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire);Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire);Diagnostic Test: R-PAct (Questionnaire);Diagnostic Test: Quick Motor Function Test;Diagnostic Test: Handheld Dynamometry (HHD);Diagnostic Test: Six-minute walk test (6MWT);Diagnostic Test: Pressure pain threshold;Diagnostic Test: Muscle ultrasound;Diagnostic Test: Vital signs;Diagnostic Test: Borg Scale;Diagnostic Test: Laboratory assessment: Creatine kinase;Diagnostic Test: Laboratory assessment: Vitamin D Level;Diagnostic Test: Laboratory assessment: calcium;Diagnostic Test: Laboratory assessment: magnesium;Diagnostic Test: Laboratory assessment: phosphate;Genetic: Genetic test: ACE polymorphism;Genetic: Genetic test: ACTN3 polymorphism;Genetic: Blood draw for optional genetic exome sequencing	LMU Klinikum	NULL	Not yet recruiting	18 Years	N/A	All	95		Germany

284. Diamond-Blackfan anemia

Clinical trials : 37 / Drugs : 110 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-006322-25-GB (EUCTR)	08/10/2012	14/08/2012	Extending the treatment of Iron Overload	A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602).	Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemia; aquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. MedDRA version: 16.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: SSP-004184AQ 50 mg Capsule Product Code: SSP-004184AQ 50 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 100 mg Capsule Product Code: SSP-004184AQ 100 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 200 mg Capsule Product Code: SSP-004184AQ 200 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 250 mg Capsule Product Code: SSP-004184AQ 250 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 375 mg Capsule Product Code: SSP-004184AQ 375 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m	Shire Development LLC	NULL	Not Recruiting			Female: yes Male: yes	1500	Phase 2	Egypt;United States;Canada;Thailand;Lebanon;Turkey;Italy;United Kingdom
2	EUCTR2010-019645-25-GB (EUCTR)	19/07/2010	16/06/2010	A 24 week trial to study the safety and tolerability of SSP-004184 in the treatment of patients with longterm iron overload who need iron chelation therapy, with the option of 72 weeks further dosing.	A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, with a 72 Week Dosing Extension. - SPD602-201	Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, ß-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. MedDRA version: 14.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: SSP-004184 50 mg Capsule Product Code: SSP-004184 50 mg INN or Proposed INN: Not assigned Other descriptive name: (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184 100 mg Capsule Product Code: SSP-004184 100 mg INN or Proposed INN: Not assigned Other descriptive name: (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184 250 mg Capsule Product Code: SSP-004184 250 mg INN or Proposed INN: Not assigned Other descriptive name: (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184 375 mg Capsule Product Code: SSP-004184 375 mg INN or Proposed INN: Not assigned Other descriptive name: (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184 500 mg Capsule Product Code: SSP-004184 500 mg INN or Proposed INN: Not assigned Other descriptive name: (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo	Shire Development LLC	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	United States;Thailand;Turkey;Italy;United Kingdom

291. Hirschsprung disease, entire colon type

Clinical trials : 14 / Drugs : 35 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03593252 (ClinicalTrials.gov)	September 1, 2018	22/5/2018	Bowel Preparation in Elective Pediatric Intestinal Surgery	Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications	Colostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel Obstruction	Drug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per os	McMaster University	NULL	Not yet recruiting	6 Months	18 Years	All	48	N/A	NULL

296. Biliary atresia

Clinical trials : 63 / Drugs : 65 - (DrugBank : 37) / Drug target genes : 45 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00007033 (ClinicalTrials.gov)	October 2000	6/12/2000	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease		Alagille Syndrome;Cholestasis;Biliary Atresia	Drug: magnesium gluconate;Drug: magnesium sulfate	National Center for Research Resources (NCRR)	Children's Hospital Medical Center, Cincinnati	Completed	3 Years	18 Years	Both	25	N/A	United States

297. Alagille syndrome

Clinical trials : 43 / Drugs : 19 - (DrugBank : 9) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00007033 (ClinicalTrials.gov)	October 2000	6/12/2000	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease		Alagille Syndrome;Cholestasis;Biliary Atresia	Drug: magnesium gluconate;Drug: magnesium sulfate	National Center for Research Resources (NCRR)	Children's Hospital Medical Center, Cincinnati	Completed	3 Years	18 Years	Both	25	N/A	United States

298. Hereditary pancreatitis

Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01142128 (ClinicalTrials.gov)	February 2009	9/6/2010	Viokase 16, Viokase16 Plus Nexium and Nexium Alone	A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis	Chronic Pancreatitis	Drug: Nexium (esomeprazole magnesium);Drug: Placebo to Nexium;Drug: Viokase 16 (pancrelipase) + Nexium;Drug: Viokase 16 + placebo to Nexium	University of Florida	AstraZeneca	Terminated	18 Years	75 Years	All	12	Phase 1	United States
2	EUCTR2006-000087-83-GB (EUCTR)	19/12/2008	04/12/2007	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2	Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis MedDRA version: 13.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1;Level: PT;Classification code 10056976;Term: Hereditary pancreatitis;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Magnesiocard 2.5mmol Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE Product Name: ANTOX (vers) 1.2 Product Code: ANTOX Other descriptive name: TOCOPHEROL INN or Proposed INN: ASCORBIC ACID Other descriptive name: SELENIUM INN or Proposed INN: METHIONINE	University of Liverpool	The Royal Liverpool and Broadgreen University Hospitals NHS Trust	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United Kingdom
3	NCT00142233 (ClinicalTrials.gov)	June 6, 2005	31/8/2005	EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis	Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis	Pancreatitis	Dietary Supplement: ANTOX (vers.)1.2;Drug: Magnesium;Other: Placebo ANTOX (vers)1.2;Other: Placebo Magnesiocard (2.5 mmol)	University Medicine Greifswald	NULL	Completed	5 Years	75 Years	All	295	Phase 3	Germany